Free Trial

RBF Capital LLC Increases Stake in Cardlytics, Inc. (NASDAQ:CDLX)

Cardlytics logo with Business Services background

RBF Capital LLC lifted its holdings in Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 64.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 803,763 shares of the company's stock after purchasing an additional 315,635 shares during the period. RBF Capital LLC owned about 1.58% of Cardlytics worth $2,982,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mirabella Financial Services LLP purchased a new stake in Cardlytics during the 4th quarter valued at approximately $4,285,000. Rangeley Capital LLC purchased a new position in Cardlytics during the fourth quarter valued at $1,187,000. Natixis bought a new stake in Cardlytics in the 4th quarter valued at $462,000. Geode Capital Management LLC lifted its stake in Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company's stock worth $3,371,000 after purchasing an additional 73,484 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Cardlytics during the 4th quarter valued at about $157,000. Hedge funds and other institutional investors own 68.10% of the company's stock.

Cardlytics Trading Down 6.3 %

Shares of NASDAQ CDLX traded down $0.10 during trading hours on Monday, hitting $1.42. 704,546 shares of the company traded hands, compared to its average volume of 1,014,569. The company's 50 day moving average price is $1.99 and its 200 day moving average price is $3.10. Cardlytics, Inc. has a 12 month low of $1.22 and a 12 month high of $15.89. The stock has a market capitalization of $73.83 million, a price-to-earnings ratio of -0.23 and a beta of 1.39. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40.

Wall Street Analyst Weigh In

CDLX has been the subject of a number of research reports. Lake Street Capital dropped their price target on Cardlytics from $5.00 to $3.00 and set a "hold" rating for the company in a research note on Thursday, March 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cardlytics in a report on Thursday, March 13th. Finally, Evercore ISI reduced their price target on shares of Cardlytics from $4.00 to $3.00 and set an "in-line" rating on the stock in a research report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Cardlytics presently has a consensus rating of "Hold" and an average price target of $6.42.

Check Out Our Latest Analysis on CDLX

Insiders Place Their Bets

In other news, CFO Alexis Desieno sold 24,778 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the transaction, the chief financial officer now owns 140,948 shares of the company's stock, valued at approximately $479,223.20. This represents a 14.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Amit Gupta sold 46,857 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the completion of the sale, the chief executive officer now owns 418,637 shares in the company, valued at approximately $1,423,365.80. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 75,315 shares of company stock valued at $254,789 over the last three months. 4.40% of the stock is owned by company insiders.

About Cardlytics

(Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Further Reading

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines